Who is the new Chief Financial Officer (CFO) of BeOne Medicines Ltd. and what is their background?

Julia Wang has been appointed as the new CFO. She has a comprehensive financial background, having served in senior finance roles at Alexion Pharmaceuticals, Quest Diagnostics, and Johnson & Johnson, including CFO positions within J&J's China pharmaceutical operations. She previously held the roles of Senior Vice President, Enterprise Optimization and Deputy CFO at BeOne Medicines since June 2020.

What is happening with the previous CFO, Howard Liang?

Howard Liang, Ph.D., has retired as CFO and Chief Strategy Officer. He will remain with the company in a consulting capacity for four months, starting July 1, 2021, to aid in the transition. His unvested stock options will continue to vest during this consulting period.

What are the key terms of Julia Wang's compensation package?

Ms. Wang's compensation includes an annual base salary of $445,000, an annual bonus target of 50% of her base salary based on performance, and equity awards, including stock options and restricted stock units (RSUs), which vest over four years. She also received a $50,000 sign-on bonus and initial equity grants in 2020.

Are there any provisions for termination or change in control for the new CFO?

Yes, Ms. Wang's employment agreement includes provisions for termination. If terminated without cause by the company or with good reason by her, she is entitled to accrued benefits, 12 months of continued base salary and health benefits, and potential acceleration of her equity awards by 12 months. This acceleration could be full if the termination occurs within 12 months following a change in control.

ONC/BEIGF 8-K: Leadership Changes

Summary

BeOne Medicines Ltd. (ONC) announced a key leadership change in its finance department via an 8-K filing on July 1, 2021. Effective June 30, 2021, Julia Wang has been appointed as the new Chief Financial Officer (CFO) and principal financial and accounting officer. Ms. Wang brings extensive financial leadership experience from prominent companies such as Alexion Pharmaceuticals, Quest Diagnostics, and Johnson & Johnson, including significant roles within J&J's pharmaceutical business in China. Concurrently, Howard Liang, Ph.D., the previous CFO and Chief Strategy Officer, retired from his executive roles. Dr. Liang will transition to a consulting role for a four-month period to ensure a smooth handover and will continue to have his outstanding unvested stock options vest during this time. This CFO transition is a significant event for investors, highlighting the company's focus on financial stewardship and continuity.

Key Highlights

1Julia Wang appointed as the new Chief Financial Officer (CFO) and principal financial/accounting officer, effective June 30, 2021.
2Ms. Wang possesses a strong financial background with experience at Alexion Pharmaceuticals, Quest Diagnostics, and Johnson & Johnson.
3Howard Liang, Ph.D., the former CFO and Chief Strategy Officer, has retired.
4Dr. Liang will continue to support the company as a consultant for four months, ensuring a transition period.
5Ms. Wang's compensation includes a base salary of $445,000, a target annual bonus of 50% of base salary, and equity awards (options and RSUs) with multi-year vesting schedules.
6Ms. Wang received a sign-on bonus of $50,000 and initial equity grants in June 2020, with further equity grants in June 2021.
7Severance provisions for Ms. Wang include up to 12 months of salary and benefits, plus potential acceleration of equity vesting under certain conditions, including a change in control.

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jul 1, 2021)

Summary

Key Highlights

Frequently Asked Questions